Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, paclitaxel albumin-bound nanoparticles (Abraxane®) cannot be endorsed for use within NHS Wales in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. |
||
|
||
Medicine details |
||
| Medicine name | paclitaxel albumin-bound nanoparticles (Abraxane®) | |
| Formulation | 5 mg/ml powder for solution for infusion | |
| Reference number | 1666 | |
| Indication | For use in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. |
|
| Company | Celgene Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 26/06/2015 | |
| Date of issue | 30/06/2015 | |